Precigen, Inc. (PGEN) Stock

Precigen, Inc., based in Germantown, Maryland, is a pioneering biotechnology company at the forefront of discovering and advancing the next generation of gene and cellular therapies within the United States. Established in 1998 and formerly known as Intrexon Corporation until January 2020, Precigen is committed to developing innovative disease-modifying therapeutics and cutting-edge technologies.

The company's diverse portfolio includes genetically engineered swine tailored for regenerative medicine applications, along with reproductive and embryo transfer technologies that support advancements in biotechnology and agriculture. Precigen also offers the UltraVector platform, integrating advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs.

Among its notable innovations, Precigen has developed mbIL15, a gene enhancing the functional characteristics of immune cells, and Sleeping Beauty, a non-viral transposon/transposase system facilitating gene delivery. The company's capabilities extend to AdenoVerse, a technology platform featuring a library of engineered adenovector serotypes, and L. lactis, a food-grade bacterium utilized in various biotechnological applications.

Precigen is recognized for its development of RheoSwitch, an inducible gene switch system enabling precise regulation of target protein expression, and tissue-specific promoters that enhance therapeutic specificity. The company's platforms also include UltraCAR-T for cancer treatment, AdenoVerse Immunotherapy for gene delivery, and ActoBiotics, genetically modified bacteria delivering proteins and peptides at mucosal sites. With collaborative agreements with entities such as Alaunos Therapeutics, Inc., Oragenics, Inc., and Castle Creek Biosciences, Precigen continues to drive innovation and expand the boundaries of biotechnology to address complex medical challenges.